Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $525.0K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $382.1K
Chief Business Officer, Senior Vice President and Director
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis
Jul 13 15
Five Prime Therapeutics, Inc. announced that the company has initiated patient dosing in its Phase 1/2 clinical trial of FPA008, a CSF1 receptor antibody, in pigmented villonodular synovitis (PVNS). During the Phase 1 dose escalation part of the trial, Five Prime will assess the safety and pharmacodynamics of multiple ascending doses of FPA008 to determine the dose for expansion. During the Phase 2 expansion phase, the company will evaluate response rate and duration, as well as measures of pain and joint function, in
approximately 30 patients. Initial data from the Phase 1 dose escalation portion are expected by late 2015 or early 2016.
Five Prime Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:30 AM
Jun 2 15
Five Prime Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
bluebird bio Enters into License Agreement with Five Prime Therapeutics
May 27 15
bluebird bio, Inc. and Five Prime Therapeutics, Inc. have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime's human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics for cancer and inflammatory diseases, while bluebird bio is a developer of gene therapies for severe genetic disorders. Under the terms of the agreement, Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|